Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul Morten Mau Sorensen"'
Autor:
Sharon Friedlander, Martin Gutierrez, Tami Rashal, Sharon Shacham, Rachid Baz, Michael R. Savona, John Kuruvilla, Thaddeus J. Unger, Nashat Y. Gabrail, Meagan A. Jacoby, Michael Wang, Peter Martin, Robert W. Carlson, Michael Kauffman, Paul Morten Mau-Sorensen, Jean Richard Saint-Martin, Lynn Savoie, Richard Stone, Ian W. Flinn, Ramiro Garzon
Publikováno v:
Blood. 129(24)
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 tr
Autor:
Thaddeus J. Unger, Nashat Y. Gabrail, Martin Gutierrez, Rachid Baz, Boris Klebanov, Tami Rashal, Sharon Shacham, Robert W. Carlson, Ramiro Garzon, Richard Stone, Karen W.L. Yee, Michael Andreeff, Trinayan Kashyap, Paul Morten Mau-Sorensen, Michael R. Savona, Nina D. Wagner-Johnston, Michael Kauffman, Jean Richard Saint-Martin, Lynn Savoie
Publikováno v:
Blood
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function, leads to nuclear accumulation of tumor suppressor proteins, and induces cancer cell death. A phase 1 dose-escalation study
Autor:
Christoffer Johansen, Paul Morten Mau Sorensen, Katrine Toubro Gad, Mette Terp Høybye, Ulrik Lassen
Publikováno v:
Gad, K T, Lassen, U N, Mau Sorensen, P M, Høybye, M T & Johansen, C 2017, ' Information when patients participate in a phase I trial : A systematic review. ', Journal of Clinical Oncology, vol. 35(5_suppl), pp. 85 . https://doi.org/10.1200/JCO.2017.35.5_suppl.85
85 Background: While phase I trials are essential for the development of new anticancer drugs, there is a limited chance of benefitting for cancer patients participating in such trials. The information dialogue is therefore of substantial importance